title: Adalimumab-induced bronchospasm: not a class effect.
authors.forename: R
authors.initials: R
authors.lastname: Janssen
authors.forename: I
authors.initials: I
authors.lastname: Krivokuca
authors.forename: A A
authors.initials: AA
authors.lastname: Kruize
authors.forename: L
authors.initials: L
authors.lastname: Koenderman
authors.forename: J-W J
authors.initials: JW
authors.lastname: Lammers
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001986:Bronchial Spasm / Q000139:chemically induced*; D000068800:Etanercept; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007074:Immunoglobulin G; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D018124:Receptors, Tumor Necrosis Factor
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept